The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
CLL
DRUG: Zanubrutinib
Progression Free Survival (PFS), PFS is defined as the duration from date of Zanubrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause, up to two years
Overall Survival, OS is defined as the time from the starting date of Zanubrutinib to the date of death due to any cause., up to two years|Time to Next Therapy (TTNT), The TTNT will be calculated as the difference between Zanubrutinib initiation date and initiation date of the first next therapy for CLL, up to two years|Adverse Events, Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations, up to two years
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China